Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q969Q6
UPID:
P2R3C_HUMAN
Alternative names:
Protein phosphatase subunit G5PR; Rhabdomyosarcoma antigen MU-RMS-40.6A/6C
Alternative UPACC:
Q969Q6; B4DEN7; D3DS97; D3DS98; Q5GJ55; Q5GJ56; Q6P4G2; Q86TZ3; Q9NWR9
Background:
Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit gamma, also known as Protein phosphatase subunit G5PR and Rhabdomyosarcoma antigen MU-RMS-40.6A/6C, plays a pivotal role in various cellular processes. It is involved in the regulation of MCM3AP phosphorylation, acts as a negative regulator of ABCB1 expression and function, and may contribute to the activation-induced cell death of B-cells. This protein's multifaceted role in biological systems makes it an intriguing subject for scientific inquiry.
Therapeutic significance:
Linked to Myoectodermal gonadal dysgenesis syndrome and Spermatogenic failure 36, Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit gamma's involvement in these diseases highlights its potential as a target for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies, offering hope for patients suffering from these conditions.